Sanofi ADR
I · Analiza AI
Pe scurt
Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].
Sanofi is a major French pharmaceutical company with $104.3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10.1 billion in free cash flow and a 5.55% dividend yield [Yahoo Finance].
Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].
Scor Sentinellis
7.4/10
Financially healthy
Capitalizare bursieră
$104.3B
Venituri (12 luni)
$46.7B
II · Știri recente
Ce a mișcat prețul
5 stories · ranked by relevance
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-18
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Yahoo Finance
- macro2026-05-18
A Look At Sanofi (ENXTPA:SAN) Valuation After Recent Share Price Weakness
Simply Wall St
- macro2026-05-18
Sanofi Deepens AI And Alzheimer’s Research While Shares Trade Below Targets
Simply Wall St
- macro2026-05-19
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Yahoo Finance
Premium · gratuit cu orice cont
The stock dropped 9% over the past month and has struggled over the past year, signaling investor concern about near-term performance despite longer-term gains [Simply Wall St]
Riscuri
5
Oportunități
6
Semnale de alarmă
2
Conducere
10
Încă 22 de constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Sanofi ADR
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 5 riscuri, 6 oportunități și 2 semnale de alarmă — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?